Product
SARS-CoV-2 protein subunit recombinant vaccine
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 in Healthy Populations Aged 18 Years and Above in IndonesiaStatus: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in IndonesiaStatus: Completed, Estimated PCD: 2022-08-02